https://peptidewire.co Daily peptide research, literature, and industry intel for biohackers en-us Tue, 16 Jun 2026 22:51:04 GMT https://peptidewire.co/issues/2026-06-16-peptide-digest A new drug lets you lose fat on tirzepatide without losing muscle. Plus: AI is designing peptides from scratch, and a Reddit study reveals the side effects gray-market reta users don't talk about. Tue, 16 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-16-peptide-digest https://peptidewire.co/issues/2026-06-15-peptide-digest Apitegromab preserved 54.9% more lean mass during tirzepatide weight loss in the EMBRAZE trial; retatrutide drops Phase 3 TRANSCEND data in Lancet; orforglipron goes head-to-head with dapagliflozin and insulin. Mon, 15 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-15-peptide-digest https://peptidewire.co/issues/2026-06-14-peptide-digest Apitegromab preserves 55% more lean mass on tirzepatide, TRANSCEND-T2D-1 delivers retatrutide Phase 3 data, three new MOTS-c papers drop, and the Secure America Act rattles peptide importers. Sun, 14 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-14-peptide-digest https://peptidewire.co/issues/2026-06-13-peptide-digest TRANSCEND-T2D-1 delivers phase 3 retatrutide data in Lancet; apitegromab preserves lean mass during tirzepatide weight loss; BPC-157 hybrid analogs show acetylcholinesterase inhibition for the first time. Sat, 13 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-13-peptide-digest https://peptidewire.co/issues/2026-06-12-peptide-digest The week GLP-1s learned to keep the muscle they burn, with a Nature Medicine myostatin-blocker trial, a Lancet triple-agonist readout, and an oral non-peptide GLP-1 head-to-head against an SGLT2. Fri, 12 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-12-peptide-digest https://peptidewire.co/issues/2026-06-10-peptide-digest Apitegromab preserves lean mass during tirzepatide weight loss (EMBRAZE); Elecoglipron SOLSTICE phase 2b data published; Semaglutide Alzheimer's evoke/evoke+ reanalysis finds signals; Retatrutide synthesis breakthrough; BPC-157, MOTS-c, Epitalon non-GLP-1 coverage continues. Wed, 10 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-10-peptide-digest https://peptidewire.co/issues/2026-06-09-peptide-digest Orforglipron ACHIEVE-2 goes head-to-head with dapagliflozin; oral GLP-1s gain clinical positioning papers; MOTS-c racks up a third ischemia-protection paper; BPC-157 I/R data reinforces cytoprotective claims; Epitalon's senolytic mechanism keeps gaining attention. Tue, 09 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-09-peptide-digest https://peptidewire.co/issues/2026-06-08-peptide-digest TRANSCEND-T2D-1 publishes phase 3 retatrutide data; CagriSema REIMAGINE program drops three simultaneous papers; BPC-157 shows protection against limb ischemia-reperfusion injury; Epitalon emerges as a senolytic candidate in lymphoma; MOTS-c gains ground in inflammatory lung disease and cardiac ischemia. Mon, 08 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-08-peptide-digest https://peptidewire.co/issues/2026-06-07-peptide-digest The retatrutide TRANSCEND-T2D-1 phase 3 monotherapy results dominate this weekend's peptide landscape — triple agonism validated in a large-scale trial. Plus: new obesity subphenotypes predict tirzepatide response, GLP-1 discontinuation dynamics parsed, and TB-500 pops up in an unexpected proteomic study of tuberculosis. Sun, 07 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-07-peptide-digest https://peptidewire.co/issues/2026-06-06-peptide-digest Tirzepatide dominates the week's literature with new data across MASLD, psoriasis, type 1 diabetes, Smith-Magenis syndrome, and binge-eating disorder. MOTS-c lands two independent papers. Orforglipron's positioning against oral semaglutide gets head-to-head analysis. And semaglutide shows early promise for opioid use disorder. Sat, 06 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-06-peptide-digest https://peptidewire.co/issues/2026-06-05-peptide-digest This week's peptide pulse: the TRANSCEND-T2D-1 phase 3 data for retatrutide is finally out — triple agonism delivers. BPC 157 shows clear muscle protection in ischemia-reperfusion. Epitalon emerges as a senolytic candidate in lymphoma. MOTS-c gets a pulmonary spotlight. And the muscle-loss problem with GLP-1s gets a new solution: 15-PGDH inhibition. Fri, 05 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-05-peptide-digest https://peptidewire.co/issues/2026-06-04-peptide-digest GLP-1 RAs may reduce chronic low back pain in obesity through anti-inflammatory mechanisms. Tirzepatide + metformin shows promise in PCOS. FLOW trial cardio-renal analysis cements semaglutide's kidney protection. Plus: tirzepatide crosses into psoriasis, type 1 diabetes, and the constipation-differential-GI safety debate gets real-world data. Thu, 04 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-04-peptide-digest https://peptidewire.co/issues/2026-06-03-peptide-digest SURPASS-CVOT delivers the GLP-1 Ceiling and GIP Dividend framework. Semaglutide-induced muscle loss may be solvable with 15-PGDH inhibition. BPC-157's ischemia-reperfusion mechanism gets rat-model validation, and epitalon finds a surprising role in lymphoma senolysis. Wed, 03 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-03-peptide-digest https://peptidewire.co/issues/2026-06-02-peptide-digest A landmark BPC-157 pharmaceutics review exposes the translational void after 30 years of research. Plus: MOTS-c preserves cardiac mitochondria, epitalon emerges as senolytic in lymphoma, and the Lancet maps GLP-1's pleiotropic reach beyond weight loss. Tue, 02 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-02-peptide-digest https://peptidewire.co/issues/2026-06-01-peptide-digest A sweeping biopharmaceutical review exposes BPC-157's core problem: it's not the biology—it's the missing pharmaceutical science. Plus MOTS-c rescues ischemic flaps, Epitalon cracks senescence-driven chemoresistance, and oral GLP-1s clear major regulatory hurdles. Mon, 01 Jun 2026 00:00:00 GMT https://peptidewire.co/issues/2026-06-01-peptide-digest https://peptidewire.co/issues/2026-05-31-peptide-digest BPC-157 has 30+ years of preclinical data and still can't get to Phase II — a new review explains why. Meanwhile, Europe backs oral Wegovy, the FDA targets compounding, and r/Peptides bans all source discussion. Sun, 31 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-31-peptide-digest https://peptidewire.co/issues/2026-05-30-peptide-digest A Mendelian randomization study in over 1 million participants links GLP-1 receptor agonism to sarcopenia and pancreatitis risk. Meanwhile, community pricing data reveals TB-500 at $20 with quality signals, and the vendor landscape shows GLP-1s commoditizing while healing peptides fragment. Sat, 30 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-30-peptide-digest https://peptidewire.co/issues/2026-05-29-peptide-digest Epitalon eliminates therapy-resistant senescent cancer cells in a first-of-its-kind lymphoma study, while a comprehensive Pharmaceutics review exposes why BPC-157 has languished in pharmaceutical limbo for three decades. Plus: the oral GLP-1 market hits its first inflection point. Fri, 29 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-29-peptide-digest https://peptidewire.co/issues/2026-05-28-peptide-digest An FDA advisory committee will meet this summer to decide the fate of BPC-157 and TB-500 in compounding pharmacies, while a new Pharmaceutics review exposes why this peptide has languished in pharmaceutical limbo for 30 years. Plus: semaglutide's off-label T1D use gets real-world scrutiny, and silk nanoparticles advance oral peptide delivery. Thu, 28 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-28-peptide-digest https://peptidewire.co/issues/2026-05-27-peptide-digest Wegovy pill sees first prescription decline while Foundayo builds through telehealth channels. China's peptide manufacturing remains unregulated and quality-variable. Wed, 27 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-27-peptide-digest https://peptidewire.co/issues/2026-05-26-peptide-digest The oral GLP-1 landscape continues to evolve with Wegovy pill seeing its first decline while Foundayo gains traction. Meanwhile, China's underground peptide manufacturing remains a quality minefield. Tue, 26 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-26-peptide-digest https://peptidewire.co/issues/2026-05-25-peptide-digest Wegovy oral prescriptions drop for the first time since launch while Lilly's Foundayo quietly builds momentum. Plus: CDER leadership shakeup, China's underground peptide market, and FDA compounding surveillance updates. Mon, 25 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-25-peptide-digest https://peptidewire.co/issues/2026-05-24-peptide-digest Nature Metabolism maps how semaglutide actually rewires your hindbrain, oral GLP-1 scripts show surprising volatility, and a ground-level China sourcing report reveals the underground reality of peptide manufacturing. Sun, 24 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-24-peptide-digest https://peptidewire.co/issues/2026-05-23-peptide-digest Wegovy pill prescriptions just fell for the first time since launch, orforglipron proves oral maintenance after injectables is real, and scientists mapped how semaglutide rewires your hindbrain. Plus: China's peptide underground gets exposed. Sat, 23 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-23-peptide-digest https://peptidewire.co/issues/2026-05-22-peptide-digest A new post hoc analysis says semaglutide rolled back epigenetic age by nearly 5 years, orforglipron showed it can maintain post-injection weight loss, and the EU just recommended oral Wegovy. Meanwhile, the peptide gray market is getting squeezed from both ends. Fri, 22 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-22-peptide-digest https://peptidewire.co/issues/2026-05-21-peptide-digest A Nature Communications post hoc analysis shows semaglutide shaved 2–5 years off epigenetic age in an HIV cohort—while a separate Nature Medicine trial proves orforglipron can hold most weight loss after stopping injectable GLP-1s. Meanwhile, high-dose tirzepatide carries an AKI signal, the China sourcing scene is uglier than advertised, and r/Peptides just banned all source talk. Thu, 21 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-21-peptide-digest https://peptidewire.co/issues/2026-05-20-peptide-digest Semaglutide shaved nearly 5 years off biological clocks in 32 weeks, oral orforglipron kept 75% of injectable weight loss, and a network meta-analysis flags acute kidney injury risk on high-dose tirzepatide. Wed, 20 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-20-peptide-digest https://peptidewire.co/issues/2026-05-20-welcome-state-of-peptides-q2-2026 A 10-min field guide to the last 90 days in peptide therapeutics — what landed, what failed, what's coming, and what biohackers actually need to know. Wed, 20 May 2026 00:00:00 GMT https://peptidewire.co/issues/2026-05-20-welcome-state-of-peptides-q2-2026 https://peptidewire.co/issues/oral-glp-1-agonists Why injectable peptides are losing ground to pills — and what that means for biohackers, payers, and the next decade of metabolic medicine. Wed, 20 May 2026 00:00:00 GMT https://peptidewire.co/issues/oral-glp-1-agonists https://peptidewire.co/issues/peptide-market-q1-2026 Where the money flows in metabolic peptides, why the compounding pharmacy era is ending, and what the gray market looks like for biohackers when the FDA actually enforces. Wed, 20 May 2026 00:00:00 GMT https://peptidewire.co/issues/peptide-market-q1-2026 https://peptidewire.co/issues/structural-basis-peptide-membrane The biophysics of peptide-membrane interaction — and why understanding it explains the entire delivery problem, from injectable insulin to oral semaglutide to BPC-157 absorption claims. Wed, 20 May 2026 00:00:00 GMT https://peptidewire.co/issues/structural-basis-peptide-membrane